Best treatment options for occult breast cancer: A meta-analysis

Objectives Occult breast cancer (OBC) is a rare malignant breast tumor. Because of the rare cases and limited clinical experience, a huge therapeutic difference has existed all over the world and standardized treatments have yet been established. Methods A meta-analysis was conducted using MEDLINE and Embase databases to identify the choice of OBC surgical procedures in all studies: (1) patients undergoing axillary lymph node dissection (ALND) or sentinel lymph node biopsy (SLNB) only; (2) patients undergoing ALND with radiotherapy (RT); (3) patients undergoing ALND with breast surgery (BS); (4) patients undergoing ALND with RT and BS; and (5) patients undergoing observation or RT only. The primary endpoints were mortality rates, the second endpoints were distant metastasis and locoregional recurrence. Results Among the 3,476 patients, 493 (14.2%) undergo ALND or SLNB only; 632 (18.2%) undergo ALND with RT; 1483 (42.7%) undergo ALND with BS; 467 (13.4%) undergo ALND RT and BS, and 401 (11.5%) undergo observation or RT only. After comparing the multiple groups, both groups 1 and 3 have higher mortality rates than group 4 (30.7% vs. 18.6%, p < 0.0001; 25.1% vs. 18.6%, p = 0.007), and group 1 has higher mortality rates than groups 2 and 3 (30.7% vs.14.7%, p < 0.00001; 30.7 vs. 19.4%, p < 0.0001). Group (1 + 3) had a prognosis advantage over group 5 (21.4% vs. 31.0%, p < 0.00001). There was no significant difference both in the distant recurrence rates and locoregional rates between group (1 + 3) and group (2 + 4) (21.0% vs. 9.7%, p = 0.06; 12.3% vs. 6.5%, p = 0.26). Conclusion On the basis of this meta-analysis, our study indicates that BS including modified radical mastectomy (MRM) and breast-conserving surgery (BCS) combined RT may appear as the optimal surgical approach in patients with OBC. RT cannot prolong both the time of distant metastasis and the local recurrences.

[1]  Y. Piao,et al.  Combined radiotherapy and chemotherapy versus radiotherapy alone in elderly patients with nasopharyngeal carcinoma , 2021, Medicine.

[2]  Haidong Zhao,et al.  Prognostic significance of occult lymph node metastases in breast cancer: a meta-analysis , 2021, BMC cancer.

[3]  K. Moore,et al.  Occult breast cancer: Where are we at? , 2020, Breast.

[4]  D. Franceschi,et al.  The Effect of Hospital Volume on Outcomes of Patients with Occult Breast Cancer , 2020, Annals of Surgical Oncology.

[5]  G. Plitas,et al.  Axillary Downstaging in Occult Primary Breast Cancer After Neoadjuvant Chemotherapy , 2020, Annals of Surgical Oncology.

[6]  Yuxiang Lin,et al.  Different Clinicopathological Characteristics and Prognostic Factors for Occult and Non-occult Breast Cancer: Analysis of the SEER Database , 2020, Frontiers in Oncology.

[7]  G. Plitas,et al.  ASO Author Reflections: Avoiding an Axillary Lymph Node Dissection: The Benefit of Neoadjuvant Chemotherapy for Occult Primary Breast Cancer , 2020, Annals of Surgical Oncology.

[8]  L. Prantl,et al.  Occult Pathologic Findings in Reduction Mammaplasty in 5781 Patients—An International Multicenter Study , 2020, Journal of clinical medicine.

[9]  Erratum: Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. , 2020, CA: a cancer journal for clinicians.

[10]  F. Macedo,et al.  ASO Author Reflections: SLNB with RT May Be Sufficient in Occult Breast Cancer after NAC , 2020, Annals of Surgical Oncology.

[11]  R. Mellor Population analysis , 2020, Nature.

[12]  Beiqun Zhao,et al.  Treatment for occult breast cancer: A propensity score analysis of the National Cancer Database. , 2019, American Journal of Surgery.

[13]  Tae Hyun Kim,et al.  Outcome of breast-conserving treatment for axillary lymph node metastasis from occult breast cancer with negative breast MRI , 2019, Breast.

[14]  M. McCarter,et al.  Analysis of the National Cancer Database Esophageal Squamous Cell Carcinoma in the United States. , 2019, The Annals of thoracic surgery.

[15]  W. Irish,et al.  The effect of local therapy on breast cancer-specific mortality of women with occult breast cancer and advanced nodal disease (N2/N3): a population analysis , 2019, Breast Cancer Research and Treatment.

[16]  D. Toppmeyer,et al.  Breast-conservation Therapy After Neoadjuvant Chemotherapy Does Not Compromise 10-Year Breast Cancer–specific Mortality , 2018, American journal of clinical oncology.

[17]  S. Xiao,et al.  Surgical Management of the Axilla in Breast Cancer Patients with Negative Sentinel Lymph Node: A Method to Reduce False-Negative Rate , 2018, World Journal of Surgery.

[18]  G. Di,et al.  Clinicopathological characteristics and treatment outcomes of occult breast cancer: a SEER population-based study , 2018, Cancer management and research.

[19]  Chanchan Gao,et al.  The efficacy and safety of targeted therapy plus fulvestrant in postmenopausal women with hormone-receptor positive advanced breast cancer: A meta-analysis of randomized-control trials , 2018, PloS one.

[20]  A. Jemal,et al.  Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries , 2018, CA: a cancer journal for clinicians.

[21]  Seigo Nakamura,et al.  High rate of occult cancer found in prophylactic mastectomy specimens despite thorough presurgical assessment with MRI and ultrasound: findings from the Hereditary Breast and Ovarian Cancer Registration 2016 in Japan , 2018, Breast Cancer Research and Treatment.

[22]  H. Iwata,et al.  Occult breast cancer may originate from ectopic breast tissue present in axillary lymph nodes , 2018, Breast Cancer Research and Treatment.

[23]  P. Yuan,et al.  Progress in targeted therapy for breast cancer , 2018, Chronic diseases and translational medicine.

[24]  San-Gang Wu,et al.  Comparison of survival outcomes of locally advanced breast cancer patients receiving post-mastectomy radiotherapy with and without immediate breast reconstruction: a population-based analysis , 2018, Cancer management and research.

[25]  M. Guggenheim,et al.  Occurrence of Occult Malignancies in Reduction Mammoplasties , 2018, Front. Surg..

[26]  Hao Wu,et al.  A retrospective study of optimal surgical management for occult breast carcinoma , 2017, Medicine.

[27]  San-Gang Wu,et al.  Comparable Survival between Additional Radiotherapy and Local Surgery in Occult Breast Cancer after Axillary Lymph Node Dissection: A Population-based Analysis , 2017, Journal of Cancer.

[28]  Xiaoxia Ma,et al.  Application of neoadjuvant chemotherapy in occult breast cancer , 2017, Medicine.

[29]  S. Feigenberg,et al.  Factors Influencing Management and Outcome in Patients with Occult Breast Cancer with Axillary Lymph Node Involvement: Analysis of the National Cancer Database , 2017, Annals of Surgical Oncology.

[30]  M. Morrow,et al.  Oncologic Outcomes After Treatment for MRI Occult Breast Cancer (pT0N+) , 2017, Annals of Surgical Oncology.

[31]  Kyubo Kim,et al.  Evaluation of the Benefit of Radiotherapy in Patients with Occult Breast Cancer: A Population-Based Analysis of the SEER Database , 2017, Cancer research and treatment : official journal of Korean Cancer Association.

[32]  M. Jacobs,et al.  Optimal Surgical Management for Occult Breast Carcinoma: A Meta-analysis , 2016, Annals of Surgical Oncology.

[33]  E. Gontier,et al.  18F-FDG PET/CT to Predict Response to Neoadjuvant Chemotherapy and Prognosis in Inflammatory Breast Cancer , 2015, The Journal of Nuclear Medicine.

[34]  Bénédicte M A Delattre,et al.  PET/MR in Breast Cancer. , 2015, Seminars in nuclear medicine.

[35]  C. Mathers,et al.  Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012 , 2015, International journal of cancer.

[36]  S. Ahn,et al.  Treatment and survival of patients with occult breast cancer with axillary lymph node metastasis: A nationwide retrospective study , 2014, Journal of surgical oncology.

[37]  S. Ahn,et al.  Survival Outcomes of Different Treatment Methods for the Ipsilateral Breast of Occult Breast Cancer Patients with Axillary Lymph Node Metastasis: A Single Center Experience , 2013, Journal of breast cancer.

[38]  M. Usel,et al.  Breast lesions in reduction mammaplasty specimens: a histopathological pattern in 534 patients , 2013, British Journal of Cancer.

[39]  B. Ljung,et al.  Breast Cancer, Version 3.2013 , 2013 .

[40]  G. Di,et al.  Treatment outcomes and unfavorable prognostic factors in patients with occult breast cancer. , 2012, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[41]  Donald L. Weaver,et al.  Effect of occult metastases on survival in node-negative breast cancer. , 2011, The New England journal of medicine.

[42]  W. Woodward,et al.  Population‐based analysis of occult primary breast cancer with axillary lymph node metastasis , 2010, Cancer.

[43]  P. V. van Diest,et al.  Micrometastases or isolated tumor cells and the outcome of breast cancer. , 2009, The New England journal of medicine.

[44]  N. Taira,et al.  Two cases of occult breast cancer in which PET-CT was helpful in identifying primary tumors , 2008, Breast cancer.

[45]  F. Schmidt Meta-Analysis , 2008 .

[46]  S. Edge,et al.  Prognosis of Occult Breast Carcinoma Presenting as Isolated Axillary Nodal Metastasis , 2007, Oncology.

[47]  S. Iacobelli,et al.  Axillary Lymph Node Nanometastases Are Prognostic Factors for Disease-Free Survival and Metastatic Relapse in Breast Cancer Patients , 2006, Clinical Cancer Research.

[48]  U. Pietrzyk,et al.  Clinical and diagnostic value of preoperative MR mammography and FDG-PET in suspicious breast lesions , 2003, European Radiology.

[49]  Yudong D. He,et al.  Gene expression profiling predicts clinical outcome of breast cancer , 2002, Nature.

[50]  J. Bryant,et al.  Preoperative chemotherapy in patients with operable breast cancer: nine-year results from National Surgical Adjuvant Breast and Bowel Project B-18. , 2001, Journal of the National Cancer Institute. Monographs.

[51]  C. Sweep,et al.  Randomized adjuvant chemotherapy trial in high-risk, lymph node-negative breast cancer patients identified by urokinase-type plasminogen activator and plasminogen activator inhibitor type 1. , 2001, Journal of the National Cancer Institute.

[52]  C. Redmond,et al.  Relation of number of positive axillary nodes to the prognosis of patients with primary breast cancer. An NSABP update , 1983, Cancer.

[53]  B. Fornage,et al.  Breast Conservation in the Setting of Contemporary Multimodality Treatment Provides Excellent Outcomes for Patients with Occult Primary Breast Cancer , 2014, Annals of Surgical Oncology.

[54]  N. Davidson,et al.  Adjuvant chemotherapy of axillary lymph-node-positive breast cancer. , 1992, Cancer treatment and research.